비교리스트

 카트 문의
시장보고서
상품코드
1625408

파라세타몰 정맥주사 시장 규모, 점유율, 동향, 산업 분석 보고서 : 적응증별, 용도별, 최종 용도별, 지역별 - 시장 예측(2025-2034년)

Paracetamol IV Market Size, Share, Trends, Industry Analysis Report: By Indication (Pain and Pyrexia), Application, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 128 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 파라세타몰 정맥주사 시장 규모는 2034년까지 11억 1,785만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

파라세타몰 정맥주사 시장 확대의 원동력은 효과적인 통증 관리 솔루션에 대한 수요 증가이며, 특히 빠른 발병이 중요한 임상 현장에서의 수요가 증가하고 있습니다. 특히 경구투여가 어려운 환자들은 경구투여보다 정맥투여 제제를 선호하고 있어 시장 수요를 크게 뒷받침하고 있습니다. 수술의 증가, 수술 후 통증 완화를 필요로 하는 만성질환의 유병률 증가, 노인 인구의 증가 등의 요인이 파라세타몰 정맥주사 제제에 대한 수요 증가에 기여하고 있습니다. 전 세계적으로 의료 인프라가 확대되면서 파라세타몰 정맥주사 시장의 성장에 크게 기여하고 있습니다.

파라세타몰 정맥주사 시장의 전망은 분명 밝으며, 약물전달의 획기적인 기술 혁신과 다양한 환자군에 대한 파라세타몰의 정맥 투여가 보다 안전하고 효과적일 수 있도록 하는 제형 기술의 발전은 큰 시장 기회를 제공하고 있습니다. 또한, 파라세타몰 정맥주사 시장의 확대는 업계 선두주자들의 전략적 R&D 투자에 의해 뒷받침되고 있습니다. 이러한 투자는 부작용을 최소화하면서 제품의 효과와 안전성을 극대화하는 데 초점을 맞추고 있으며, 파라세타몰 정맥주사 제제가 통증 관리 프로토콜에서 더 나은 선택이 될 수 있는 기반을 마련하고 있습니다.

파라세타몰 정맥주사 시장 보고서 하이라이트

2024년 파라세타몰 정맥주사 시장은 수술 후 또는 외상 후 효과적이고 즉각적인 진통에 대한 높은 수요로 인해 적응증별로는 통증 분야가 큰 비중을 차지했습니다.

외래 진료에 대한 선호도가 증가하고 클리닉에서 정맥 내 통증 관리 옵션의 가용성이 증가함에 따라 최종 사용 기반 클리닉 부문은 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다.

2024년 기준 북미가 파라세타몰 정맥주사 시장 점유율을 독점할 것으로 예상되는데, 이는 이 지역 전체에서 효과적인 통증 관리에 대한 중요성이 강조되고 있기 때문입니다.

아시아태평양 시장은 헬스케어 투자 증가로 인해 예측 기간 동안 큰 성장을 보일 것으로 예상됩니다.

세계 주요 시장 기업으로는 Mallinckrodt(Mallinckrodt Pharmaceuticals), Cipla Inc. Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., Abbott, Sanofi, Bristol-Myers Squibb Company 등이 있습니다.

목차

제1장 소개

제2장 주요 요약

제3장 조사 방법

제4장 세계의 파라세타몰 정맥주사 시장 인사이트

  • 시장 현황
  • 파라세타몰 정맥주사 시장 역학
    • 성장 촉진요인과 기회
      • 외과수술 증가
      • 만성 통증과 발열 증가
    • 성장 억제요인과 과제
      • 대체약 선택사항
  • PESTEL 분석
  • 파라세타몰 정맥주사 시장 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 파라세타몰 정맥주사 시장 : 적응증별

  • 주요 조사 결과
  • 소개
  • 통증
  • 발열

제6장 세계의 파라세타몰 정맥주사 시장 : 용도별

  • 주요 조사 결과
  • 소개
  • 외과수술
  • 비외과적

제7장 세계의 파라세타몰 정맥주사 시장 : 최종 용도별

  • 주요 조사 결과
  • 소개
  • 병원
  • 클리닉
  • 기타

제8장 세계의 파라세타몰 정맥주사 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 파라세타몰 정맥주사 시장 평가 : 지역별, 2020-2034년
  • 북미
    • 북미 : 적응증별, 2020-2034년
    • 북미 : 용도별, 2020-2034년
    • 북미 : 최종 용도별, 2020-2034년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 적응증별, 2020-2034년
    • 유럽 : 용도별, 2020-2034년
    • 유럽 : 최종 용도별, 2020-2034년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 적응증별, 2020-2034년
    • 아시아태평양 : 용도별, 2020-2034년
    • 아시아태평양 : 최종 용도별, 2020-2034년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 적응증별, 2020-2034년
    • 중동 및 아프리카 : 용도별, 2020-2034년
    • 중동 및 아프리카 : 최종 용도별, 2020-2034년
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 적응증별, 2020-2034년
    • 라틴아메리카 : 용도별, 2020-2034년
    • 라틴아메리카 : 최종 용도별, 2020-2034년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제9장 경쟁 구도

  • 확대와 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 개요

  • Mallinckrodt(Mallinckrodt Pharmaceuticals)
  • Cipla Inc.
  • Lupin
  • Dr Reddy's Laboratories Ltd.
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Limited
  • Novartis AG
  • Pfizer Inc.
  • Abbott
  • Sanofi
  • Bristol-Myers Squibb Company
ksm 25.02.06

The paracetamol IV market size is expected to reach USD 1,117.85 million by 2034, according to a new study by Polaris Market Research. The report "Paracetamol IV Market Share, Size, Trends, Industry Analysis Report: By Indication (Pain and Pyrexia), Application, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising demand for effective pain management solutions, particularly in clinical settings where rapid onset is crucial, drives the paracetamol IV market expansion. The preference for intravenous (IV) formulations over oral routes, especially for patients unable to take medication orally, significantly supports market demand. Factors such as increasing surgical procedures, a growing prevalence of chronic conditions requiring postoperative pain relief, and the expanding geriatric population contribute to the rising need for paracetamol IV formulations. The global expansion of healthcare infrastructure is significantly propelling the paracetamol IV market growth, as more hospitals and clinics are becoming equipped to provide IV pain management.

The paracetamol IV market outlook is undeniably positive, with significant market opportunities fueled by groundbreaking innovations in drug delivery and enhanced formulation techniques that ensure intravenous (IV) paracetamol is both safer and more effective for diverse patient groups. Furthermore, the IV paracetamol market expansion is supported by strategic investments in research and development from leading industry players. These investments are specifically geared toward maximizing product efficacy and safety while minimizing side effects, firmly establishing IV paracetamol as a better option in pain management protocols.

Paracetamol IV Market Report Highlights

In terms of indication, in 2024, the pain segment accounted for a larger share of the paracetamol IV market revenue due to the high demand for effective and immediate pain relief in post-surgical and trauma cases.

The clinics segment, based on end use, is expected to witness the highest CAGR during the forecast period due to the growing preference for outpatient care and the increasing availability of intravenous pain management options in clinic settings.

In 2024, North America dominated the paracetamol IV market share due to the strong focus on effective pain management practices across the region.

The Asia Pacific market is expected to witness significant growth during the forecast period due to increasing healthcare investments.

A few global key market players are Mallinckrodt (Mallinckrodt Pharmaceuticals), Cipla Inc., Lupin, Dr Reddy's Laboratories Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., Abbott, Sanofi, and Bristol-Myers Squibb Company.

Polaris Market Research has segmented the paracetamol IV market report on the basis of indication, application, end use, and region:

By Indication Outlook (Revenue, USD Million; 2020-2034)

  • Pain
  • Pyrexia

By Application Outlook (Revenue, USD Million; 2020-2034)

  • Surgical
  • Non-Surgical

By End Use Outlook (Revenue, USD Million; 2020-2034)

  • Hospitals
  • Clinics
  • Others

By Regional Outlook (Revenue, USD Million; 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Paracetamol IV Market Insights

  • 4.1. Paracetamol IV Market - Market Snapshot
  • 4.2. Paracetamol IV Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Surgical Procedures
      • 4.2.1.2. Rising Prevalence of Chronic Pain and Fever
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Alternative Drug Option
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Paracetamol IV Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Paracetamol IV Market, by Indication

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
  • 5.3. Pain
    • 5.3.1. Global Paracetamol IV Market, by Pain, by Region, 2020-2034 (USD Million)
  • 5.4. Pyrexia
    • 5.4.1. Global Paracetamol IV Market, by Pyrexia, by Region, 2020-2034 (USD Million)

6. Global Paracetamol IV Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Paracetamol IV Market, by Application, 2020-2034 (USD Million)
  • 6.3. Surgical
    • 6.3.1. Global Paracetamol IV Market, by Surgical, by Region, 2020-2034 (USD Million)
  • 6.4. Non-surgical
    • 6.4.1. Global Paracetamol IV Market, by Non-surgical, by Region, 2020-2034 (USD Million)

7. Global Paracetamol IV Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
  • 7.3. Hospital
    • 7.3.1. Global Paracetamol IV Market, by Hospital, by Region, 2020-2034 (USD Million)
  • 7.4. Clinics
    • 7.4.1. Global Paracetamol IV Market, by Clinics, by Region, 2020-2034 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Paracetamol IV Market, by Others, by Region, 2020-2034 (USD Million)

8. Global Paracetamol IV Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Paracetamol IV Market Assessment, By Geography, 2020-2034 (USD Million)
  • 8.3. Paracetamol IV Market - North America
    • 8.3.1. North America: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
    • 8.3.2. North America: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
    • 8.3.3. North America: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.3.4. Paracetamol IV Market - U.S.
      • 8.3.4.1. U.S.: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.3.4.2. U.S.: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.3.4.3. U.S.: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.3.5. Paracetamol IV Market - Canada
      • 8.3.5.1. Canada: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.3.5.2. Canada: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.3.5.3. Canada: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
  • 8.4. Paracetamol IV Market - Europe
    • 8.4.1. Europe: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
    • 8.4.2. Europe: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
    • 8.4.3. Europe: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.4.4. Paracetamol IV Market - UK
      • 8.4.4.1. UK: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.4.4.2. UK: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.4.4.3. UK: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.4.5. Paracetamol IV Market - France
      • 8.4.5.1. France: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.4.5.2. France: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.4.5.3. France: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.4.6. Paracetamol IV Market - Germany
      • 8.4.6.1. Germany: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.4.6.2. Germany: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.4.6.3. Germany: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.4.7. Paracetamol IV Market - Italy
      • 8.4.7.1. Italy: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.4.7.2. Italy: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.4.7.3. Italy: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.4.8. Paracetamol IV Market - Spain
      • 8.4.8.1. Spain: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.4.8.2. Spain: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.4.8.3. Spain: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.4.9. Paracetamol IV Market - Netherlands
      • 8.4.9.1. Netherlands: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.4.9.2. Netherlands: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.4.9.3. Netherlands: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.4.10. Paracetamol IV Market - Russia
      • 8.4.10.1. Russia: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.4.10.2. Russia: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.4.10.3. Russia: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.4.11. Paracetamol IV Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.4.11.2. Rest of Europe: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.4.11.3. Rest of Europe: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
  • 8.5. Paracetamol IV Market - Asia Pacific
    • 8.5.1. Asia Pacific: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
    • 8.5.2. Asia Pacific: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
    • 8.5.3. Asia Pacific: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.5.4. Paracetamol IV Market - China
      • 8.5.4.1. China: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.5.4.2. China: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.5.4.3. China: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.5.5. Paracetamol IV Market - India
      • 8.5.5.1. India: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.5.5.2. India: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.5.5.3. India: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.5.6. Paracetamol IV Market - Malaysia
      • 8.5.6.1. Malaysia: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.5.6.2. Malaysia: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.5.6.3. Malaysia: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.5.7. Paracetamol IV Market - Japan
      • 8.5.7.1. Japan: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.5.7.2. Japan: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.5.7.3. Japan: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.5.8. Paracetamol IV Market - Indonesia
      • 8.5.8.1. Indonesia: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.5.8.2. Indonesia: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.5.8.3. Indonesia: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.5.9. Paracetamol IV Market - South Korea
      • 8.5.9.1. South Korea: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.5.9.2. South Korea: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.5.9.3. South Korea: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.5.10. Paracetamol IV Market - Australia
      • 8.5.10.1. Australia: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.5.10.2. Australia: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.5.10.3. Australia: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.5.11. Paracetamol IV Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.5.11.2. Rest of Asia Pacific: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.5.11.3. Rest of Asia Pacific: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
  • 8.6. Paracetamol IV Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
    • 8.6.2. Middle East & Africa: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
    • 8.6.3. Middle East & Africa: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.6.4. Paracetamol IV Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.6.4.2. Saudi Arabia: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.6.4.3. Saudi Arabia: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.6.5. Paracetamol IV Market - UAE
      • 8.6.5.1. UAE: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.6.5.2. UAE: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.6.5.3. UAE: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.6.6. Paracetamol IV Market - Israel
      • 8.6.6.1. Israel: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.6.6.2. Israel: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.6.6.3. Israel: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.6.7. Paracetamol IV Market - South Africa
      • 8.6.7.1. South Africa: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.6.7.2. South Africa: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.6.7.3. South Africa: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.6.8. Paracetamol IV Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.6.8.2. Rest of Middle East & Africa: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.6.8.3. Rest of Middle East & Africa: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
  • 8.7. Paracetamol IV Market - Latin America
    • 8.7.1. Latin America: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
    • 8.7.2. Latin America: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
    • 8.7.3. Latin America: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.7.4. Paracetamol IV Market - Mexico
      • 8.7.4.1. Mexico: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.7.4.2. Mexico: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.7.4.3. Mexico: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.7.5. Paracetamol IV Market - Brazil
      • 8.7.5.1. Brazil: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.7.5.2. Brazil: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.7.5.3. Brazil: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.7.6. Paracetamol IV Market - Argentina
      • 8.7.6.1. Argentina: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.7.6.2. Argentina: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.7.6.3. Argentina: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)
    • 8.7.7. Paracetamol IV Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Paracetamol IV Market, by Indication, 2020-2034 (USD Million)
      • 8.7.7.2. Rest of Latin America: Paracetamol IV Market, by Application, 2020-2034 (USD Million)
      • 8.7.7.3. Rest of Latin America: Paracetamol IV Market, by End Use, 2020-2034 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Mallinckrodt (Mallinckrodt Pharmaceuticals)
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Cipla Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Lupin
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Dr Reddy's Laboratories Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Aurobindo Pharma
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sun Pharmaceutical Industries Limited
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis AG
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Pfizer Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Abbott
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sanofi
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Bristol-Myers Squibb Company
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제